NovaBridge Biosciences stock gained 1.12 percent on October 2

Published on 10/04/2026 at 17:07 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

NovaBridge Biosciences stock traded at USD 1.35 on Nasdaq on October 2, 2026, within a USD 1.31 to USD 6.79 yearly range. Cash and investments reached USD 216 million.

NBP, US44975P1030, Illustration mit AI erstellt.

NovaBridge Biosciences stock (ISIN US44975P1030) gained 1.12 percent to USD 1.35 on Nasdaq on October 2, 2026, while the company held USD 216 million in cash and investments as of June 30, 2026. The cash position gives the clinical-stage biotech room to advance its oncology and ophthalmology programs into the next development phase.

Cash supports late-stage plans

According to ScanX on September 18, 2026, NovaBridge reported USD 216 million in cash and investments as of June 30, 2026. The balance consisted of USD 191 million in cash and cash equivalents and USD 25 million in equity investments, while the balance sheet was debt-free.

The company plans to use that liquidity for clinical milestones through 2028. Givastomig, its oncology program, received FDA Fast Track designation in June 2026, and management targeted a Phase 3 start as early as the fourth quarter of 2026, subject to planning and financing, according to ScanX.

Analyst target stays far higher

Markets Insider reported that H.C. Wainwright analyst Andres Y. Maldonado reiterated a Buy rating and a USD 9.00 price target for NovaBridge. The same report described the broader consensus as Moderate Buy with a USD 9.00 average target.

Against the USD 1.35 Nasdaq price on October 2, 2026, that target lies 566.7 percent above the stock. The gap reflects the market's demand for clinical progress before the pipeline value can be translated into commercial results.

Stock remains near yearly low

NovaBridge stock traded at USD 1.35 with a session range of USD 1.33 to USD 1.36, compared with a previous close of USD 1.34. The 52-week range of USD 1.31 to USD 6.79 places the latest price near the lower end of the year's span, while volume reached 252,895 shares.

Market capitalization stood at USD 156.2 million on October 2, 2026. For investors, the central balance is clear: USD 216 million of liquidity supports development, while the valuation still depends on execution across givastomig and the VIS-101 ophthalmology program.